Literature DB >> 26341799

Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses.

Yi Tao1, Jian Xue2, Bin Jiang3, Hao-Bing Zhang4, Shu-Hua Xiao5.   

Abstract

The purpose of the present study is to understand the pharmacokinetic feature of mefloquine measured by erythrocytes and plasma in Schistosoma japonicum (S. j.)-infected mice and non-infected mice after oral administration of the drug at single doses. A high-performance liquid chromatography (HPLC) method was used to measure the plasma and erythrocyte concentrations of mefloquine at varying intervals posttreatment. Our results demonstrated that in non-infected mice treated orally with mefloquine at an ineffective dose of 50 mg/kg or effective dose of 200 mg/kg for 2-72 h, the erythrocyte-to-plasma ratios of mefloquine were 5.8-11.2 or 2-14.2. On the other hand, in S. j.-infected mice treated with the same single doses of the drug, the erythrocyte and plasma drug concentration ratios were 3.1-4.6 or 2.9-8.5, manifesting that either in infected mice or in non-infected mice that received oral mefloquine resulted in higher concentration of mefloquine in erythrocytes than that in plasma. Unexpectedly, under oral administration of mefloquine at a higher single dose of 200 mg/kg, the pharmacokinetic parameter C max values for plasma from S. j.-infected and non-infected mice were 1.6 ± 0.3 and 2.0 ± 0.4 μg/mL, respectively, which were below the determined in vitro LC50 (50 % lethal concentration) value of 4.93 μg/mL. Therefore, the plasma concentration of mefloquine may display a little effect against schistosomes during the treatment. Although the values of T 1/2 and AUC0-∞ for erythrocytes were significantly longer and higher in infected mice than those of corresponding non-infect mice that received the same single mefloqine dose of 50 mg/kg, the C max value was only 2.6 ± 0.4 μg/mL lower than the determined in vitro LC50, which may explain why this low single dose is ineffective against schistosomes in vivo. After administration of higher mefloquine dose of 200 mg/kg, the C max value for erythrocytes in infected mice was 30 % (7.4 ± 0.7 versus 10.7 ± 2.7 μg/mL) lower than that in the corresponding non-infected mice, but its level was above the determined in vitro LC95 (95 % lethal concentration) value of 6.12 μg/mL. Meanwhile, longer T 1/2 value of 159.2 ± 129.3 h in infected mice led to significant increase in AUC0-∞ value (1969.3 ± 1057.7 vs 486.4 ± 53.0 μg/mL·h), relative to corresponding non-infected mice. In addition, the mean residence time (MRT0-∞) in infected mice was also significantly longer than that in non-infected mice. All these results may beneficial for the treatment. According to the results, we suggest that higher ratios of mefloquine concentration in erythrocytes to plasma may offer a way to transport mefloquine to the worm gut through ingestion of erythrocytes by the worms, where the gut is the site for displaying the effect by mefloquine.

Entities:  

Keywords:  Erythrocyte; Mefloquine; Mouse; Pharmacokinetics; Plasma; Schistosoma japonicum

Mesh:

Substances:

Year:  2015        PMID: 26341799     DOI: 10.1007/s00436-015-4696-4

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  63 in total

1.  Antimalarials. 7. Bis(trifluoromethyl)- -(2-piperidyl)-4-quinolinemethanols.

Authors:  C J Ohnmacht; A R Patel; R E Lutz
Journal:  J Med Chem       Date:  1971-10       Impact factor: 7.446

2.  Susceptibility of Schistosoma japonicum to different developmental stages to praziquantel.

Authors:  S H Xiao; W J Yue; Y Q Yang; J Q You
Journal:  Chin Med J (Engl)       Date:  1987-09       Impact factor: 2.628

3.  In vivo and in vitro experiments on the effects of praziquantel on Schistosoma mansoni. A light and electron microscopic study.

Authors:  H Mehlhorn; B Becker; P Andrews; H Thomas; J K Frenkel
Journal:  Arzneimittelforschung       Date:  1981

4.  On the mechanism for the red-cell accumulation of mefloquine, an antimalarial drug.

Authors:  R C San George; R L Nagel; M E Fabry
Journal:  Biochim Biophys Acta       Date:  1984-03-23

5.  Disposition of mefloquine and enpiroline is highly influenced by a chronic Schistosoma mansoni infection.

Authors:  Katrin Ingram; Urs Duthaler; Mireille Vargas; William Ellis; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

6.  Tegumental alterations of adult Schistosoma japonicum harbored in mice treated with a single oral dose of mefloquine.

Authors:  Shu-hua Xiao; Jian Xue; Bing-gui Shen
Journal:  Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi       Date:  2010-02

7.  [Comparative observation on inhibition of hemozoin formation and their in vitro and in vivo anti-schistosome activity displayed by 7 antimalarial drugs].

Authors:  Jian Xue; Bin Jiang; Cong-Shan Liu; Jun Sun; Shu-Hua Xiao
Journal:  Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi       Date:  2013-06

8.  Inhibition of heme aggregation by chloroquine reduces Schistosoma mansoni infection.

Authors:  Marcus F Oliveira; Joana C P d'Avila; Antonio J Tempone; Juliana B R Correa Soares; Franklin D Rumjanek; Antonio Ferreira-Pereira; Sergio T Ferreira; Pedro L Oliveira
Journal:  J Infect Dis       Date:  2004-07-20       Impact factor: 5.226

9.  Mefloquine in combination with hemin causes severe damage to adult Schistosoma japonicum in vitro.

Authors:  Shu-hua Xiao; Chunhua Qiao; Jian Xue; Lili Wang
Journal:  Acta Trop       Date:  2013-12-18       Impact factor: 3.112

10.  Further study on mefloquine concerning several aspects in experimental treatment of mice and hamsters infected with Schistosoma japonicum.

Authors:  Shu-hua Xiao; Jing-yan Mei; Pei-ying Jiao
Journal:  Parasitol Res       Date:  2009-10-02       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.